Simple Tests to Predict Hepatic Fibrosis in Nonalcoholic Chronic Liver Diseases
| Autor: | Sun-Young Jun, Sang-Hoon Park, Woon Geon Shin, Kyo-Sang Yoo, Jong Pyo Kim, Kyoung Oh Kim, Joon Ho Moon, Tai Ho Hahn, Jae One Jung, Choong Kee Park, Cheol Hee Park, Jong Hyeok Kim |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
METAVIR Fibrosis Score
medicine.medical_specialty Hepatology Receiver operating characteristic business.industry Gastroenterology Hepatitis B medicine.disease Confidence interval Fibrosis Internal medicine Nonalcoholic fatty liver disease Medicine Original Article business Hepatic fibrosis Serum markers |
| Zdroj: | KoreaMed |
| ISSN: | 2005-1212 1976-2283 |
| Popis: | BACKGROUND/AIMS Several simple tests for hepatic fibrosis employ indirect markers. However, the efficacy of using direct and indirect serum markers to predict significant fibrosis in clinical practice is inconclusive. We analyzed the efficacy of a previously reported indirect marker of hepatic fibrosis - the aspartate aminotransferase to platelet ratio index (APRI) - in patients with nonalcoholic chronic liver diseases (CLDs). METHODS A total of 134 patients who underwent a percutaneous liver biopsy with a final diagnosis of chronic hepatitis B (n=93), chronic hepatitis C (n=18), or nonalcoholic fatty liver disease (n=23) were enrolled. A single-blinded pathologist staged fibrosis from F0 to F4 according to the METAVIR system, with significant hepatic fibrosis defined as a METAVIR fibrosis score of >/=2. RESULTS The mean area under the receiver operating characteristic curve (AUROC) of APRI for predicting significant fibrosis in nonalcoholic CLDs was 0.84 [95% confidence interval (CI), 0.78-0.91]. APRI yielded the highest mean AUROC in the patients with chronic hepatitis B (0.85; 95% CI, 0.771-0.926). The positive predictive value of APRI >/=1.5 for predicting significant fibrosis was 89%. The negative predictive value of APRI |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|